This article is more than 5 years old. Information may no longer be current.

Allergan third quarter includes $1.3 billion net sales, dividend for shareholders

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Allergan announced $0.81 diluted earnings per share attributable to stockholders in its third quarter operating results, compared with a diluted loss of $2.21 per share attributable to stockholders in the third quarter of 2010, according to a news release.

As a result, the company's board of directors declared a dividend of $0.05 per share.

In total, the company reported $1.3 billion in total product net sales, an increase of 10% over sales in the third quarter of 2010, the release said.

"We are encouraged by the continuing good growth of our global cash pay businesses in the quarter," David E.I. Pyott, Allergan's board chairman, president and CEO, said in the release.

Key developments for the quarter include the National Institute for Health and Clinical Excellence issuing final guidance for Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of macular edema due to central retinal vein occlusion and for some cases of branch retinal vein occlusion.